

# Watch Melanoma Experts Discuss Clinical Trials and the Emerging RP1 Treatment

The Melanoma Research Alliance's latest video talk is "Oncolytic Immunotherapy, Clinical Trials & the Emerging RP1 Treatment."

July 15, 2025 By [Melanoma Research Alliance](#)

---

By Renee Orcione, associate director of communications and engagement at Melanoma Research Alliance

On July 1, Melanoma Research Alliance (MRA) hosted another installment in our [MRA Meet-Ups series](#), where we regularly connect with the melanoma community to discuss important topics, share insights and experiences, and ask questions. The session, called "Oncolytic Immunotherapy, Clinical Trials, & the Emerging RP1 Treatment," featured [Dr. Yana Najjar](#) of UPMC Hillman Cancer Center.

Moderated by MRA's Director of Communications and Engagement Dana Deighton, the discussion explored the science behind oncolytic immunotherapies, the critical role of clinical trial participation, and the promise of RP1 — a next-generation therapy being studied in combination with nivolumab for advanced melanoma as part of the ongoing [IGNYTE-3 clinical trial](#) (NCT06264180). This exciting combination is currently under priority review by the FDA, following the acceptance of a Biologics License Application (BLA) earlier this year. The BLA submission was supported by primary data from the IGNYTE clinical trial, and a final decision from the FDA is expected in the coming months. If approved, RP1 could be a groundbreaking new option for patients with advanced melanoma.

## Topics discussed included:

- An overview of oncolytic immunotherapies, how they work, and how they differ from the immunotherapies that are the current standard of care in advanced melanoma,

- The science behind the new biologic RP1 and how the modified herpes simplex virus is used,
- The process of administering the investigational RP1 treatment to patients,
- A deep dive into the ongoing IGNYTE-3 clinical trial, including study goals, eligibility criteria, and more,
- Prior data that has led to the acceptance of a Biologics License Application (BLA) earlier this year,
- & more!

Watch the full recording at the top of this page [or on YouTube](#).

For those looking for a clinical trial option for patients with advanced melanoma that has progressed on certain immunotherapies (anti-PD-1 & anti-CTLA-4), please visit [clinicaltrials.gov](https://clinicaltrials.gov) to learn about the ongoing IGNYTE-3 trial.

[This post](#) was originally published July 2, 2025, by the [Melanoma Research Alliance](#). It is republished with permission.

---

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.cancerhealth.com/blog/watch-melanoma-experts-discuss-clinical-trials-emerging-rp1-treatment>